Abstract
A wide variety of neoplasms can affect the central nervous system. Surgical management is impacted by tumor biology and anatomic location. In this review, an overview is presented of common and clinically significant CNS tumor types based on anatomic location.
Keywords: Central nervous system, tumor, surgery, glioma, neoplasm, leukemia.
[1]
American brain Tumor Association. Available from: http://www. abta.org/about-us/news/brain-tumor-statistics/(Accessed on: 20 Oct 2016)..
[2]
Ellison L, Janz T. Childhood cancer incidence and mortality in Canada. Available from: http://www.statcan.gc.ca/pub/82-624-x/2015001/article/14213-eng.htm (Accessed on: 20 Oct 2016)..
[3]
Buckner JC, Brown PD, O’Neill BP, et al. Central nervous system tumors. Mayo Clin Proc 2007; 82(10): 1271-86.
[4]
Meningioma: Stages and Grades. Available from: http://www. cancer.net/cancer-types/meningioma/stages-and-grades (Accessed on: 22 Oct 2016)..
[5]
Kleihues P, Cavenee WK, Eds. WHO Classification of tumors: Pathology and genetics of tumors of the nervous system. : IARC Press Germany 2000.
[6]
Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957; 20: 22-39.
[7]
Walcott BP, Nahed BV, Brastianos PK, et al. Radiation Treatment for WHO Grade II and III Meningiomas. Front Oncol 2013; 3: 227.
[8]
Fowd CF, Halback VV, Higashida RT. Meningiomas: the role of preoperative angiography and embolization. Neurosurg Focus 2003; 15: 1-4.
[9]
Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500.
[10]
Bindal RK, Sawaya R, Leavens ME, et al. Surgical treatment of multiple brain metastases. J Neurosurg 1993; 79(2): 210-6.
[11]
Ohgaki H, Kleihues P. Genetic Pathways to Primary and Secondary Glioblastoma. Am J Pathol 2007; 170(5): 1445-53.
[12]
Verhaak RG, Hoadley KA, Purdom E, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 2010; 17(1): 98.
[13]
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352(10): 997-1003.
[14]
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
[15]
Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma: prognosis, extent of resection, and survival. J Neurosurg 2001; 95(2): 190-8.
[16]
Freije WA, Castro-Vargas E, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004; 64: 6503-10.
[17]
Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-9.
[18]
The Cancer Genome Altas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372: 2481-98.
[19]
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131: 803-20.
[20]
Macaulay RJ. Impending impact of molecular pathology on classifying adult diffuse gliomas. Cancer Control 215; 22(2): 200-5..
[21]
Aghi MK, Nahed BV, Sloan AE, et al. The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2015; 125(3): 503-30.
[22]
Nimsky C, Ganslandt O, Hastreiter P, et al. Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery. Neurosurgery 2005; 56(1): 130-7.
[23]
De Benedictis A, Moritz-Gasser S, Duffau H. Awake mapping optimizes the extent of resection for low-grade gliomas in eloquent areas. Neurosurgery 2010; 66(6): 1074-84.
[24]
Hervey-Jumper SL, Berger MS. Maximizing safe resection of low and high-grade glioma. J Neurooncol 2016; 130(2): 269-82.
[25]
Barbosa BJ, Mariano ED, Batista CM, et al. Intraoperative assistive technologies and extent of resection in glioma surgery: A systematic review of prospective controlled studies. Neurosurg Rev 2015; 38(2): 217-27.
[26]
Carrabba G, Fava E, Guissani C, et al. Cortical and subcortical motor mapping in rolandic and perirolanddic glioma surgery: Impact on postoperative morbidity and extent of resection. J Neurosurg Sci 2007; 51(2): 45-51.
[27]
Kapsalaki EZ, Verganelakis D, Kapsalakis IZ, Gotsis ED, Fountas KN. The role of functional mri in intracranial glioma resectionAvailable from: http://cdn.intechopen.com/pdfs/31411.pdf (Accessed on: Oct 27, 2016)..
[28]
Fenchel M, Beschorner R, Naegele T, et al. Primarily solid intraventricular brain tumors. Eur J Rad 2012; 81: e688-96.
[29]
Pan DH, Lee CC. The management of incidental central neurocytoma. Neurosurg Clin N Am 2015; 26: 57-66.
[30]
Rhoton A. Cranial anatomy and surgical approaches. In: Congress of Neurological Surgeons. Oxford University Press UK 2003.
[31]
Thomas AG, Koumellis P, Dineen RA. The fornix in health and disease: an imaging review. Radiographics 2011; 31: 1107-21.
[33]
Pettorini BL, Frassanito P, Caldarelli M, et al. Molecular pathogenesis of craniopharyngioma: switching from a surgical approach to a biological one. Neurosurg Focus 2010; 28(4)E1
[34]
Lopez-Serna R, Gomez-Amador JL, Barges-Coll J, et al. Treatment of craniopharyngioma in adults: Systematic analysis of a 25-year experience. Arch Med Res 2012; 43: 347-55.
[35]
Zada GZ, Lin N, Ojerholm E, et al. Craniopharyngioma and other cystic epithelial lesions of the sellar region: A review of clinical, imaging and histopathological relationships. Neurosurg Focus 2010; 28(4)E4
[36]
Lopez-Serna R, Gomez-Amador JL, Barges-Coll J, et al. Treatment of craniopharyngioma in adults: systematic analysis of a 25-year experience. Arch Med Res 2012; 43: 347-55.
[37]
Yang I, Sughrue ME, Rutkowski MJ, et al. Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurg Focus 2010; 28(4)E5
[38]
Mortini P, Gagliardi F, Boari N, et al. Surgical strategies and modern therapeutic options in the treatment of cranio-pharyngiomas. Crit Rev Onc Hem 2013; 88: 514-29.
[39]
Buchfelder M, Schlaffer SM, Lin F, et al. Surgery for craniopharyngioma. Pituitary 2013; 16: 18-25.
[40]
Bresson D, Herman P, Polivka M, et al. Sellar lesions/pathology. Otolaryngol Clin N Am 2016; 49: 63-93.
[41]
Farrell CJ, Nyquist GG, Farag AA, et al. Principles of Pituitary Surgery. Otolaryngol Clin N Am 2016; 49: 95-106.
[42]
Sonabend AM, Bowden S, Bruce JN. Microsurgical resection of pineal tumors. J Neurooncol 2016; 130(2): 351-66.
[43]
Choudhri AF, Siddiqui A, Klimo P. Pediatric cerebellar tumors: emerging imaging techniques and advances in understanding genetic features. Neuroimag Clin N Am 2016; 26: 459-69.
[44]
Coluccia D, Figuereido C, Isik S, et al. Medulloblastoma: Tumor biology and relevance to treatment and prognosis paradigm. Curr Neurol Neurosci Rep 2016; 2016: 43.
[45]
Shih RY, Smirniotopoulos JG. Posterior fossa tumors in adult patients. Neuroimag Clin N Am 2016; 26: 493-510.
[46]
Carlson ML, Link MJ, Wanna GB, et al. Management of sporadic vestibular schwannoma. Otolaryngol Clin N Am 2015; 48: 407-22.
[47]
Joaquim AF, Powers A, Laufer I, et al. An update in the management of spinal metastases. Arq Neuropsiquiatr 2015; 73(9): 795-802.
[48]
Feiz-Erfan I, Rhines LD, Weinberg JS. The role of surgery in the management of metastatic spine tumors. Sem Onc 2008; 35(2): 108-17.
[49]
Cole JS, Patchell RA. Metastatic epidural spinal cord compression. Lancet Neurol 2008; 7: 459-66.
[50]
Samartzis D, Gillis CC, Shih P, et al. Intramedullary spinal cord tumors: part I – epidemiology, pathophysiology and diagnosis. Global Spine J 2015; 5: 425-35.
[51]
Samartzis D, Gillis CC, Shih P, et al. Intramedullary spinal cord tumors: Part II – management options and outcomes. Global Spine J 2016; 6: 176-85.
26